Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-12059473-B2
Application number	US-201917042838-A
Country	US
Kind code	B2
Filing date	Mar 29, 2019
Priority date	Mar 29, 2018
Publication date	Aug 13, 2024
Grant date	Aug 13, 2024

Abstract

The invention relates to prostate specific membrane antigen humanized antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.

First claim

What is claimed:

1. An anti-prostate specific membrane antigen (anti-PSMA) antibody comprising a heavy chain sequence selected from the group consisting of SEQ ID NOs: 8, 10, 12 and 14 and a light chain sequence selected from the group consisting of SEQ ID NOs: 9, 11, 13 and 15.

2. The anti-PSMA antibody of claim 1 , wherein the light chain sequence is SEQ ID NO: 9.

3. An anti-prostate specific membrane antigen (anti-PSMA) antibody comprising a heavy chain sequence selected from the group consisting of SEQ ID NOs: 8, 10, 12 and 14 and a light chain sequence selected from the group consisting of SEQ ID NOs: 9, 11, 13 and 15,wherein the heavy chain sequence comprises a non-naturally encoded amino acid.

4. The anti-PSMA antibody of claim 3 , wherein the non-naturally encoded amino acid is para-acetyl phenylalanine, p-nitrophenylalanine, p-sulfotyrosine, p-carboxyphenyl alanine, o-nitrophenylalanine, m-nitrophenylalanine, p-boronyl phenylalanine, o-boronylphenylalanine, m-boronylphenylalanine, p-aminophenylalanine, o-aminophenylalanine, m-aminophenylalanine, p-acylphenylalanine, o-acylphenylalanine, m-acylphenylalanine, p-OMe phenylalanine, o-OMe phenylalanine, m-OMe phenylalanine, p-sulfophenylalanine, o-sulfophenylalanine, m-sulfophenylalanine, 5-nitro His, 3-nitro Tyr, 2-nitro Tyr, nitro substituted Leu, nitro substituted His, nitro substituted De, nitro substituted Trp, 2-nitro Trp, 4-nitro Trp, 5-nitro Trp, 6-nitro Trp, 7-nitro Trp, 3-aminotyrosine, 2-aminotyrosine, O-sulfotyrosine, 2-sulfooxyphenylalanine, 3-sulfooxyphenylalanine, o-carboxyphenylalanine, m-carboxyphenyl alanine, p-acetyl-L-phenylalanine, a p-propargyl-phenylalanine, O-methyl-L-tyrosine, L-3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, tri-O-acetyl-G1cNAcβ-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine or p-propargyloxy-phenylalanine.

5. The anti-PSMA antibody of claim 4 , wherein the non-naturally encoded amino acid is p-acetyl-L-phenylalanine.

6. The anti-PSMA antibody of claim 3 , wherein the non-naturally encoded amino acid is incorporated at position 114 according to Kabat numbering of the heavy chain sequence.

7. A method of treating a subject having a PSMA-expressing cancer cell or cancer comprising: administering to the subject an effective amount of an antibody drug conjugate to treat the PSMA-expressing cancer cell or cancer, wherein the antibody drug conjugate comprises the anti-PSMA antibody of claim 3 conjugated to a drug-linker via the non-naturally encoded amino acid; wherein the drug-linker has the following structure:

8. The method of claim 7 , further comprising providing to the subject a therapeutic agent.

9. The method of claim 8 , wherein the therapeutic agent is a chemotherapeutic agent, hormonal agent, antitumor agent, immunostimulatory agent, immunomodulator, corticosteroid or combination thereof.

10. The method of claim 9 , wherein the therapeutic agent is a hormonal agent, and wherein the hormonal agent is enzalutamide.

11. An antibody drug conjugate comprising a humanized anti-prostate specific membrane antigen (anti-PSMA) antibody conjugated to at least one drug-linker, wherein the at least one drug-linker comprises a cytotoxic agent;
wherein the anti-PSMA antibody comprises a heavy chain sequence selected from the group consisting of SEQ ID NOs: 8, 10, 12 and 14 and a light chain sequence selected from the group consisting of SEQ ID NOs: 9, 11, 13 and 15; and the conjugation occurs via a non-naturally encoded amino acid incorporated in the heavy chain sequence.

12. The antibody drug conjugate of claim 11 , wherein the cytotoxic agent is a dolastatin, dolastatin derivative or analog thereof.

13. The antibody drug conjugate of claim 6 , wherein the dolastatin, dolastatin derivative or analog thereof is monomethyl auristatin F or monomethyl auristatin E.

14. The antibody drug conjugate of claim 11 , wherein the at least one drug-linker has the following structure:

15. A method of reducing or inhibiting tumor growth or progression in a PSMA-expressing cancer or cancer cell comprising contacting the PSMA-expressing cancer or cancer cell with an effective amount of the antibody drug conjugate of claim 11 .

16. The method of claim 15 , further comprising contacting the PSMA-expressing cancer or cancer cell with an effective amount of a therapeutic agent.

17. The method of claim 16 , wherein the therapeutic agent is a chemotherapeutic agent, hormonal agent, antitumor agent, immunostimulatory agent, immunomodulator, corticosteroid or combination thereof.

18. The method of claim 17 , wherein the hormonal agent is enzalutamide.

19. A pharmaceutical composition comprising the antibody drug conjugate of claim 11 and at least one pharmaceutically acceptable adjuvant, binder, buffer, carrier, diluent or excipient.

20. The pharmaceutical composition of claim 19 further comprising a chemotherapeutic agent, hormonal agent, antitumor agent, immunostimulatory agent, immunomodulator, corticosteroid or combination thereof.

21. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition further comprises the hormonal agent, and wherein the hormonal agent is enzalutamide.

22. An antibody drug conjugate comprising an anti-prostate specific membrane antigen antibody (anti-PSMA antibody) conjugated to a drug-linker, wherein the conjugation occurs via a para-acetyl phenylalanine incorporated in the heavy chain sequence of the antibody, wherein the anti-PSMA antibody comprises the heavy chain sequence of SEQ ID NO: 8 and the light chain sequence of SEQ ID NO: 9,in which the para-acetyl phenylalanine is incorporated at heavy chain position A114 according to Kabat numbering, and wherein the drug-linker has the following structure:

Assignees

• Ambrx Inc

Inventors

• Bhowmik Shivarupam
• Wang Jianing
• Xia Jinming
• Brady William
• Tian Feng

Classifications

• A61K31/4166

  having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin · CPC title

• A61K47/68031

  the drug being an auristatin · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• A61P13/08

  of the prostate · CPC title